Bio-Rad Laboratories Inc (BIO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bio-Rad Laboratories Inc stock (BIO) is currently trading at $273.60. Bio-Rad Laboratories Inc PE ratio is 9.82. Bio-Rad Laboratories Inc PS ratio (Price-to-Sales) is 2.86. Analyst consensus price target for BIO is $324.00. WallStSmart rates BIO as Hold.
- BIO PE ratio analysis and historical PE chart
- BIO PS ratio (Price-to-Sales) history and trend
- BIO intrinsic value — DCF, Graham Number, EPV models
- BIO stock price prediction 2025 2026 2027 2028 2029 2030
- BIO fair value vs current price
- BIO insider transactions and insider buying
- Is BIO undervalued or overvalued?
- Bio-Rad Laboratories Inc financial analysis — revenue, earnings, cash flow
- BIO Piotroski F-Score and Altman Z-Score
- BIO analyst price target and Smart Rating
Bio-Rad Laboratories Inc
📊 No data available
Try selecting a different time range
BIO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Bio-Rad Laboratories Inc (BIO)
BIO trades 55% above its Graham fair value of $189.38, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Bio-Rad Laboratories Inc (BIO) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/book, profit margin. Concerns around operating margin and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Bio-Rad Laboratories Inc (BIO) Key Strengths (5)
Trading below book value, meaning the market prices it less than net assets
Keeps $29 of every $100 in revenue as net profit
90.37% of shares held by major funds and institutions
Good growth relative to its price
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Bio-Rad Laboratories Inc (BIO) Areas to Watch (5)
Earnings declining -83.00%, profits shrinking
Very thin margins with limited operational efficiency
Revenue growing slowly at 3.90% annually
Moderate profitability with room for improvement
Revenue is fairly priced at 2.86x sales
Supporting Valuation Data
Bio-Rad Laboratories Inc (BIO) Detailed Analysis Report
Overall Assessment
This company scores 60/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Profit Margin, Institutional Own.. Valuation metrics including PEG Ratio (1.19), Price/Book (0.96) suggest the stock is attractively priced. Profitability is solid with Profit Margin at 29.40%.
The Bear Case
The primary concerns are EPS Growth, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (2.86) suggest expensive pricing. Growth concerns include Revenue Growth at 3.90%, EPS Growth at -83.00%, which may limit upside. Profitability pressure is visible in Return on Equity at 10.80%, Operating Margin at 8.87%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 10.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 3.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Price/Book, Profit Margin) and negatives (EPS Growth, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BIO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BIO's Price-to-Sales ratio of 2.86x trades 87% above its historical average of 1.53x (95th percentile), historically expensive. The current valuation is 13% below its historical high of 3.3x set in Aug 2018, and 314% above its historical low of 0.69x in Feb 2009.
WallStSmart Analysis Synopsis
Data-driven financial summary for Bio-Rad Laboratories Inc (BIO) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Bio-Rad Laboratories Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 2.6B with 4% growth year-over-year. Profit margins are strong at 29.4%, reflecting pricing power and operational efficiency.
Key Findings
Generating 119M in free cash flow and 165M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 0.21 indicates a conservative balance sheet with 532M in cash.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Bio-Rad Laboratories Inc.
Bottom Line
Bio-Rad Laboratories Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:12:48 AM
About Bio-Rad Laboratories Inc(BIO)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.